Neurocea is developing a proprietary, first-in-class, Phase 3-ready oral drug to prevent falls in Parkinson’s Disease patients.
1Bergen G, Stevens MR, Burns ER. Falls and Fall Injuries Among Adults Aged ≥65 Years — United States, 2014. MMWR Morbidity and Mortality Weekly Report.
2Allen NE, Schwarzel AK, Canning CG. Recurrent Falls in Parkinson’s Disease: A Systematic Review. Parkinsons Disease.
3Jager TE, Weiss HB, Coben JH, Pepe PE. Traumatic Brain Injuries Evaluated in U.S. Emergency Departments, 1992-1994. Academic Emergency Medicine.
4Important Facts about Falls. Centers for Disease Control and Prevention. Published February 10, 2017. Accessed June 18, 2020.
Developing differentiated therapeutics for the treatment and prevention of falls and other movement disorders. Neurocea’s lead compound is NP002, a Phase 3-ready proprietary formulation of nicotine.
We are currently seeking partners to support the development and commercialization of NP002.
Your message has been sent.
We will follow up shortly.
Input your search keywords and press Enter.